Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Switching Strategy With Raltegravir + ABC / 3TC in Controlled HIV-1 Infection: Observational Retrospective Study at 48 Weeks - KIRAL Study

NCT03158077 is registered in ClinicalTrials.gov with Fundacion SEIMC-GESIDA as lead sponsor.

NCT NCT03158077
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03158077 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Switching Strategy With Raltegravir + ABC / 3TC in Controlled HIV-1 Infection: Observational Retrospective Study at 48 Weeks - KIRAL Study
Lead sponsor
Fundacion SEIMC-GESIDA
Phase
Observational
Overall status
Completed
Start date
November 15, 2016
Completion date
April 20, 2017
Enrollment
467 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

hiv infections